We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Learn how doctors monitor Keytruda's effectiveness using scans, blood tests, and symptom changes. Understand pseudoprogression and the role of side effects in assessing treatment success for cancer patients.

Keytruda, known medically as pembrolizumab, is a powerful immunotherapy drug used to treat various types of cancer. It works by harnessing your own immune system to identify and attack cancer cells. For patients undergoing this treatment, a crucial question arises: how do you know if Keytruda is actually working? This article aims to provide a clear and practical understanding for Indian patients about the signs and monitoring methods used to assess Keytruda's effectiveness, along with what to expect during treatment.
Keytruda is an immune checkpoint inhibitor. Cancer cells can sometimes hide from the immune system by using 'checkpoints' – proteins that prevent immune cells from attacking them. Keytruda blocks these checkpoints, essentially releasing the brakes on your immune system, allowing it to recognize and fight cancer more effectively. This mechanism means Keytruda doesn't directly kill cancer cells but rather empowers your body's natural defenses.
It's important to understand that the signs of Keytruda working can be subtle and may not always be immediately apparent. Unlike some treatments that cause rapid, noticeable changes, immunotherapy often works gradually.
This is one of the primary ways doctors monitor treatment effectiveness. Regular CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) scans are performed to check the size of tumors. Ideally, these scans will show that tumors are shrinking or at least not growing.
Important Note: Pseudoprogression
Sometimes, in the initial stages of treatment, imaging scans might show that tumors appear larger. This phenomenon is called pseudoprogression. It happens because the immune cells are infiltrating the tumor, which can make it look bigger on a scan temporarily. This does not mean the treatment is failing; in fact, it can sometimes be a sign that the immune system is responding. Doctors are trained to interpret these scans and will conduct further tests if pseudoprogression is suspected.
Regular blood tests are conducted before, during, and after Keytruda treatment. These tests help doctors:
While not always a direct indicator, a gradual improvement in cancer-related symptoms can be a positive sign. For example, if you were experiencing pain, fatigue, or shortness of breath due to the cancer, and these symptoms begin to lessen, it could suggest the treatment is effective. However, symptom improvement alone is not the sole measure of success.
Even if tumors aren't shrinking, if scans show that the cancer is stable and not growing or spreading, this is considered a successful outcome with Keytruda. The goal of immunotherapy is often to control the cancer and extend the time it remains stable.
Keytruda works by stimulating the immune system, and sometimes, side effects like inflammation can occur. These inflammatory side effects (e.g., inflammation of the lungs, colon, or skin) can sometimes be an indicator that the immune system is active and responding to the drug. However, it is crucial to understand that the absence of side effects does not mean Keytruda is not working. Some patients respond very well to Keytruda with minimal or no noticeable side effects.
If you experience any new or worsening symptoms, it's vital to report them to your doctor immediately, as they may need to be managed.
Immunotherapy drugs like Keytruda often work more slowly than traditional treatments like chemotherapy. This is because they rely on your immune system, which takes time to mobilize and attack cancer cells effectively. You might not 'feel' Keytruda working, but your doctor will be monitoring its progress through tests. Significant responses can sometimes take weeks or months to become apparent on scans.
Keytruda treatment typically lasts for a maximum of 2 years. However, if the treatment is effective and the side effects are manageable, your doctor may recommend continuing treatment for longer than 2 years. The decision is always based on your individual response and overall health.
It is essential to maintain regular follow-up appointments with your oncology team. They are best equipped to interpret test results and assess your response to Keytruda. You should consult your doctor immediately if you experience:
Disclaimer: This information is for educational purposes only and does not substitute professional medical advice. Always discuss your treatment options and concerns with your qualified healthcare provider.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026